Research note
TB-500 and Thymosin Beta-4: Why a Fragment Cannot Stand In for the Whole Protein
TB-500 is a small acetylated fragment; thymosin beta-4 is a 43-residue protein that most studies actually used. How to tell which one a vial really holds.
Thymosin beta-4 (Tβ4) is a 43-residue protein found inside cells, with a mass near 4,960 Da. What catalogues call TB-500 is a brief N-acetylated fragment weighing 889.02 Da. They overlap in sequence, yet they are not interchangeable — and much of the work quoted in support of "TB-500" was really done with the full protein. Their masses differ about five-fold, which also makes it easy to establish what a given vial contains.
Comparing the two molecules
The seven-residue peptide corresponds to LKKTETQ, the stretch of Tβ4 most strongly associated with actin binding. That stretch is necessary for the contact, but a heptapeptide cannot rebuild an interface that the 43-residue protein drapes along an entire actin monomer. Labelling the fragment an actin sequesterer therefore overstates, at minimum, what such a small molecule can do structurally. See our glossary entry on fragments.
Which molecule the published biology is really about
The well-known Tβ4 data — the heart findings of a high-profile 2004 study, corneal and skin wound-healing models, work on hair follicles, assays of endothelial cell migration — all came from intact, largely recombinant thymosin beta-4. The development programmes that reached clinical testing, including eye and skin formulations, were likewise based on the whole protein. That literature is extensive and legitimate, and not one part of it examines the seven-residue fragment.
There are papers on the fragment itself, chiefly on what the motif contributes to cell motility and pro-angiogenic signalling in cell culture. That is real evidence, but it is a distinct and much thinner body of data. Any summary that invokes "TB-500 research" and goes on to describe heart or cornea outcomes has silently substituted one compound for another.
The design implication is straightforward: a hypothesis built on full-length Tβ4 biology cannot be tested with the fragment. Our explainer on TB-500 gives the structural background.
Why beta-thymosins resist being cut down
The reason the short peptide cannot replace the protein is structural, not just a matter of naming. Unbound, beta-thymosins have no fixed fold; they stretch out only on contact with actin, when an amino-terminal helix, a middle region carrying LKKTETQ and a carboxy-terminal part each settle onto a different surface of the monomer. Binding energy is distributed along the full chain. Excise seven residues and a recognition element survives, while the scaffold that places it correctly is gone — consistent with the much weaker binding reported for isolated motif peptides compared with the whole protein.
The lesson applies to peptide fragments generally, not just to this pair. Reproducing a sequence does not guarantee reproducing its activity, and whoever asserts that it does must supply the evidence. Wherever a short catalogue peptide carries the name of a bigger parent molecule, the same caution holds: the fragment needs its own data before it can claim the parent’s.
A naming problem in research supply
In the research trade, "TB-500" is a product label rather than a defined chemical, and vendors have attached it to both molecules — some to the heptapeptide, some to intact Tβ4. Either choice can be legitimate, but an experiment that does not record which molecule it used is not reproducible.
The COA answers the question at once. An MS signal near 889 Da, or a doubly charged ion at about 445, means you have the heptapeptide. A mass of roughly 4,960 Da, typically seen as a spread of multiply charged peaks across several m/z values, means the whole protein. The two cannot be mistaken for each other. Our guide to MS identity testing shows how to read the spectrum; see also the general COA reading guide and the glossary note on molecular weight (Da).
A word on the acetyl cap. Tβ4 made by cells is naturally acetylated at its amino terminus, and the research heptapeptide reproduces that — which is why the catalogue name includes it and why the measured mass is 42 Da higher than for the uncapped sequence. See the glossary entry on acetylation.
Handling the fragment in practice
With a mass of 889.02 Da, the heptapeptide is compact, strongly polar and readily water-soluble — easier to handle than much of the range. Its sequence also makes a quick stability assessment possible: no cysteine, methionine or tryptophan, so disulfide scrambling, oxidation and photodegradation are of little concern. Glutamine and threonine are the residues worth watching if solutions are kept for long periods.
Converting to moles is simple too: 5 mg is about 5.62 µmol before any net-content correction, many more moles than 5 mg of a peptide of 4–5 kDa. Any assay that sets the fragment against the full protein must therefore be run on a molar basis — by weight, 5 mg of the heptapeptide holds around five and a half times the moles in 5 mg of Tβ4.
We supply TB-500 research vials of 5, 10 and 20 mg, an oral research format as TB-500 capsules, and a fixed-ratio combination in the BPC-157 + TB-500 blend. Our comparison article sets it against BPC-157, the other much-studied repair peptide, and the whole category is listed under tissue repair peptides.
How to describe it in a methods section
Name the compound by sequence and measured mass rather than by a trade nickname. "Ac-LKKTETQ, observed [M+H]+ 890.0, lot XXXX" is unambiguous; "TB-500" is not. When your question depends on the biology of full-length thymosin beta-4, source the intact protein and say so. When it is about the motif as such, state that you used the fragment. One line of text is enough, and it prevents a whole class of misreadings later on.
Questions
Are TB-500 and thymosin beta-4 the same thing?
No. Thymosin beta-4 is a 43-residue protein of roughly 4,960 Da, while TB-500 as commonly supplied is an acetylated heptapeptide of 889.02 Da matching the actin-binding motif region. Part of the sequence is shared, but the masses differ about five-fold, and one cannot be assumed to behave like the other.
How do I find out which molecule a vial contains?
Check the MS data on the COA. A signal near 889 Da, or a doubly charged ion around 445, identifies the heptapeptide. A neutral mass close to 4,960 Da, usually seen as a series of multiply charged peaks, identifies intact thymosin beta-4. The numbers are too far apart to mix up.
Does the fragment bind and sequester actin like the full protein?
Structurally there is no basis for assuming it does. The protein holds actin through a long contact surface along the monomer, and a seven-residue peptide cannot reproduce that, even though LKKTETQ lies at the centre of the interaction. Describing the fragment as an actin sequesterer claims more than its size permits.
Which molecule did the famous cardiac and corneal studies use?
Intact thymosin beta-4, largely recombinant. Those experiments, and the clinical development programmes for ophthalmic and dermal uses that followed, all worked with the complete protein. Attributing them to the heptapeptide is a common error in review-style summaries.
Why is TB-500 acetylated at the N-terminus?
Thymosin beta-4 produced in cells has an acetylated amino terminus, and the research fragment mirrors this. The acetyl group adds 42 Da relative to the uncapped sequence, which accounts for the measured 889.02 Da and for the Ac-LKKTETQ notation in the catalogue name.
Should the fragment and the protein be compared by mass or in molar units?
Molar units, without exception. Equal weights of the two contain very different numbers of molecules — roughly five and a half times more for the fragment — so a mass-based comparison misrepresents the amounts involved and makes the data uninterpretable.